Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
- Published In:
- Expert review of endocrinology & metabolism, 15(6), 379-394 (2020)
- Authors:
- Frías, Juan P(2)
- Database ID:
- RPEP-04805
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04805APA
Frías, Juan P. (2020). Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.. Expert review of endocrinology & metabolism, 15(6), 379-394. https://doi.org/10.1080/17446651.2020.1830759
MLA
Frías, Juan P. "Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.." Expert review of endocrinology & metabolism, 2020. https://doi.org/10.1080/17446651.2020.1830759
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide: a glucose-dependent insulinotropic polypeptide ..." RPEP-04805. Retrieved from https://rethinkpeptides.com/research/frias-2020-tirzepatide-a-glucosedependent-insulinotropic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.